Company Overview and News

Stop missing out on important events!

Fintel provides real time notifications of important company events such as major investments (13D/G filings), insider trades (SEC form 4), and important SEC filings. Sign up and create your company alerts for free.

Headline News

Orthocell secures European patent for unique tissue repair technology

Orthocell Ltd (ASX:OCC) has been issued a European patent entitled ‘Method of Tissue Repair’, protecting the company’s proprietary method of combining cartilage cells and scaffolds.

Orthocell secures European market authorisation for medical device

Orthocell Ltd (ASX:OCC) has received the European regulatory approval (CE Mark) for its CelGro collagen medical device.

Orthocell's European regulatory approval may be on the horizon

Orthocell Ltd (ASX:OCC) has been granted a trading halt by the ASX this morning, pending details in relation to its application for European regulatory approval (CE Mark) of its CelGro® collagen medical device.

Orthocell granted European patent for tissue repair technology

Orthocell (ASX:OCC) has received a European patent for its pipeline ‘Cell Factory’ technology, which produces tissue specific growth factors and bioactive proteins to enhance tissue repair.

Orthocell Ltd set to trial cell therapy injection for tennis elbow

Orthocell Ltd (ASX:OCC) will move ahead with a study comparing surgery for severe tennis elbow to Orthocell’s cell therapy Ortho-ATI injection, after receiving ethics approval to conduct the study. The primary endpoint of the study is to show that a single non-invasive treatment of Ortho-ATI is superior or equivalent to the more costly and invasive surgical intervention for the repair of severe, treatment-resistant Lateral Epicondylitis.

Appendix 4C - quarterly